Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von JPMorgan Chase & Co. 

Mersana Therapeutics diskutieren

Mersana Therapeutics

WKN: A2DTR7 / Symbol: MRSN / Name: Mersana Therapeutics / Aktie / Small Cap /

1,27 €
1,17 %

Einschätzung Buy
Rendite (%) 3,36 %
Kursziel 9,45
Veränderung
Endet am 16.03.24

Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $10.00 price target on the stock.
Ratings data for MRSN provided by MarketBeat

Mersana Therapeutics, Inc. (NASDAQ: MRSN) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
Ratings data for MRSN provided by MarketBeat

Einschätzung Buy
Rendite (%) -16,99 %
Kursziel 4,61
Veränderung
Endet am 04.12.24

Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating. They now have a $5.00 price target on the stock, up previously from $1.00.
Ratings data for MRSN provided by MarketBeat

Einschätzung Buy
Rendite (%) -74,52 %
Kursziel 5,54
Veränderung
Endet am 28.02.25

Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $6.00 price target on the stock.
Ratings data for MRSN provided by MarketBeat

Einschätzung Buy
Rendite (%) -74,52 %
Kursziel 8,30
Veränderung
Endet am 28.02.25

Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Truist Financial Co. from a "hold" rating to a "buy" rating. They now have a $9.00 price target on the stock.
Ratings data for MRSN provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 4,48
Veränderung
Endet am 27.08.25

Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its price target lowered by analysts at Citigroup Inc. from $6.00 to $5.00. They now have a "buy" rating on the stock.
Ratings data for MRSN provided by MarketBeat